Precision BioSciences (DTIL) shares were up nearly 27% in recent trading Friday, a day after its partner iEcure reported positive data on its in vivo gene insertion program and upgrade Friday from BMO Capital.

BMO Capital upgraded the company's stock to outperform from market perform, with a $34 price target.

iEcure reported positive data from the phase 1/2 study in the first patient treated with ECUR-506 for neonatal onset OTC deficiency, a hereditary metabolic disorder.

The treatment was well-tolerated overall, with only asymptomatic transaminitis noted at four weeks, which was managed with immunosuppressive therapy and resolved within another four weeks, it added.

Price: 5.70, Change: +1.20, Percent Change: +26.67